
|Articles|February 1, 2019
- Pharmaceutical Executive-02-01-2019
- Volume 39
- Issue 2
Pharmaceutical Executive, February 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive February 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
Q&A: Regulatory Reform in Chinaalmost 7 years ago
China: A Change in Attitudealmost 7 years ago
New Roads to Chinaalmost 7 years ago
Closing the Pharma and Digital Health Dividealmost 7 years ago
A Leading Man’s Next Actalmost 7 years ago
Two Steps Forwardalmost 7 years ago
Let the Drug Pricing Games Beginalmost 7 years ago
Mixed Outlook for China Life Sciencesalmost 7 years ago
CFIUS Reform’s Impact on Biopharmaalmost 7 years ago
Op-Ed: Opening the Golden DoorNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Roche’s Refresh
2
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
3
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
4
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
5




